СЛОВО,Abstract:,Lysosomal,integral,membrane,protein-2,"(LIMP-2),",encoded,by,the,SCARB2,"gene,",is,specific,lysosomal,receptor,for,glucocerebrosidase,enzyme.,Association,between,rs6812193,and,rs68250047,of,with,PD,has,been,shown,in,genetic,"studies,",including,large,genome-wide,association,studies.,The,aim,current,study,was,to,determine,whether,rs8475,are,associated,Russia.,were,genotyped,a,total,604,patients,(65,positive,(fPD),539,negative,family,history,(sPD)),413,controls,also,17,GBA,mutations,(PD-GBA),18,asymptomatic,mutation,carriers,(GBA-Carriers).,expression,measured,real-time,PCR,CD45+,blood,cells,part,individuals,studied,groups.,No,linkage,disequilibrium,Russian,population.,Increased,risk,TT,variant,(OR,=,2.02;,p,<,0.001),found,sPD,but,not,fPD.,age,at,onset,(AAO),PD.,level,decreased,GBA-PD,GBA-Carriers,compared,(padjusted,"0.02,",padjusted,"0.003,",respectively),0.013),no,significant,difference,controls.,modified,rs8475.,In,"conclusion,",status.,modifier,AAO,do,influence,on,mRNA,could,be,independent,"status.
","Buspirone,",partial,agonist,"5-HT1aR,",due,potential,antinociceptive,properties,can,useful,abdominal,pain,treatment,IBS,patients.,Pain-related,effects,buspirone,mediated,"5-HT1aRs,",located,within,nucleus,tractus,solitarius.,5-HT1aR,involvement,transmission,NTS,unclear.,objective,our,evaluate,NTS.,Using,model,urethane-anesthetized,"rats,",two,types,pain-related,neurons,responding,noxious,colorectal,distension,(CRD),excitatory,inhibitory,sustained,patterns,evoked,activity,revealed.,Buspirone,"(1.0–4.0 mg kg−1,",iv),complex,time-,dose-depended,action,CRD-induced,neuron,responses.,inhibits,responses,inverts,dose,4.0,"buspirone,",effect,attenuates.,CRD-evoked,completely,blocked,an,intra-cerebroventricular,administration,"WAY100,635.",change,this,agonist.,supraspinal,5-HT1a,receptors,"however,",its,does,dependents,these,receptors.,We,proposed,that,involved,anti-,or,pronociceptive,"pain.
","Background
",MicroRNA,(miRNAs),participate,pathogenesis,coronary,artery,disease,"(CAD).
","Objective
",To,expressions,myocardial,serum,"miRNA-27а,","miRNA-133а,",miRNA-203,CAD,"patients.
","Method
",This,cross-sectional,observational,comprised,100,subjects,(60.9 ± 1.0 years;,67%,men).,right,atrial,"miRNA-27a,",miRNA,"-133a,",80,referred,elective,bypass,graft,surgery,(CABG),20,control,scheduled,heart,valve,analyzed,using,polymerase,chain,"reaction.
","Results
",There,correlation,SYNTAX,score,I,index,(r = 0.693;,p < .001).,Patients,≥3,lesions,had,significantly,higher,than,1–2,vessel,myocardium,(miRNA-27a:,234.62 ± 29.51,vs.,182.39 ± 19.62,relative,unit,(REU);,miRNA-133а:,127.53 ± 13.41,111.35 ± 12.31,REU;,miRNA-203:,5.25 ± 0.96,4.71 ± 0.67,р < 0.05);,same,11.41 ± 3.85,4.82 ± 1.82,8.42 ± 2.43,4.35 ± 1.23,145.71 ± 15.73,43.70 ± 9.67,р < 0.05).,decision,tree,method,established,multivessel,increased,five-fold,if,>101.00,REU,"(OR,",5.90;,95%,"CI,",2.34–9.46;,"p < .001).
","Conclusions
",Both,CABG,non-CAD,subjects.,corresponds,strongly,correlated,extent,"atherosclerosis.
",A,series,binuclear,PdII,carbene,complexes,synthesized,via,cis-[PdCl2(CNXyl)2],(1),"benzo-1,3-thiazol-2-amines",(2–6),structurally,characterized.,every,case,reaction,leads,mixture,"regioisomers,",which,able,interconvert.,regioisomerization,diaminocarbene,species,showed,it,first-order,"reaction,","is,",occurs,"intramolecularly,",Hammett,function.,Electron-withdrawing,substituents,benzothiazole,moiety,as,well,increasing,solvent,polarity,accelerate,reaction.,donor,strength,correlates,less,isomerization,rates.,Based,obtained,activation,parameters,defined,interchange/dissociative,process,type.,combined,approach,kinetic,mass,spectrometric,studies,allowed,conclusion,rate-determining,step,breaking,carbon–nitrogen,bond,fragment,"complex.
","Aims
",Type,2,diabetes,mellitus,(T2DM),ranks,top,10,causes,mortality,worldwide.,key,factor,T2DM,vascular,complications,endothelial,dysfunction.,It,characterized,vessels,motor,disruption,endothelium-derived,factors,imbalance.,morphological,molecular,heterogeneity,greatly,affects,changes,occurring,T2DM.,"Therefore,",we,conducted,comparative,bed,"T2DM.
",Main,"methods
",Male,Wistar,rats,fed,high-fat,diet,"20 weeks,",followed,single,streptozotocin,injection,(20 mg/kg).,confirmed,oral,glucose,tolerance,"test.
",Key,"findings
",dose-dependent,contraction,increase,third-order,mesenteric,arterioles,response,serotonin,phenylephrine.,These,exhibited,decrease,acetylcholine-dependent,relaxation,guanylate,cyclase,At,"time,",femoral,arteries,tendency,relaxation.,plasma,analysis,revealed,low,bioavailable,nitric,oxide,high,levels,endothelin-1,"ROS.
","Significance
","knowledge,",conjunction,features,"course,",allow,further,targeted,approaches,development,prevention,"disease.
",Lorlatinib,novel,potent,ALK,"inhibitor,",only,few,reporting,results,clinical,"use.
","Methods
",describes,outcomes,lorlatinib,35,non-small,cell,lung,cancer,"rearrangements,",who,"(n = 5),",1,(n = 26),none,(n = 4),prior,tyrosine,kinase,inhibitors,received,mainly,compassionate,use,"program.
",Objective,tumor,(OR),(DC),registered,15/35,(43%),33/35,(94%),"patients,",respectively;,brain,metastases,particularly,responsive,(OR:,22/27,(81%);,DC:,27/27,(100%)).,Median,progression,free,survival,(PFS),estimated,21.8,"months,",median,overall,(OS),approached,70.1,months.,Only,4,out,experienced,adverse,effects;,them,benefit,from,lorlatinib.,PFS,OS,no-adverse-events,users,strikingly,lower,remaining,(1.1,months,23.7,10.5,"reached,",0.0001,both,comparisons).,translocation,variants,known,28,patients;,there,statistical,V.1,V.3,rearrangements,regard,"PFS.
","Conclusion
",Use,excellent,"outcomes,",however,caution,must,taken,experiencing,"drug.
",three,bariatric,interventions,infarct,size,tested,rat,type,(T2DM).,evaluated,no-reflow,phenomenon,dysfunction,caused,Rats,assigned,into,groups:,without,"surgery,","sham-operated,",ileal,"transposition,",Roux-en-Y,gastric,"bypass,",sleeve,gastrectomy.,Oral,"tolerance,",glucagon-like,"peptide-1,",insulin,measured.,Six,weeks,after,animals,subjected,ischemia-reperfusion,histochemical,determination,"(IS),","zone,",stasis,area,size.,Vascular,wire,"myography.
",All,reductions,animal,body,weight,resulted,compensation.,partially,normalized,peptide-1,attenuated,IS,smaller,Bariatric,provided,additional,limitation,alone.,surgeries,reversed,T2DM-induced,enhanced,contractile,5-hydroxytryptamine.,Sleeve,gastrectomy,synthase,contribution,endothelium-dependent,vasodilatation,reduction,zone,infarct-limiting,"effect,",augmented,contractility,typical,"together,",suggest,may,have,beneficial,cardiovascular,"diseases.
",present,investigates,event-related,oscillations,underlying,motion-onset,(MOR),sounds,moving,different,velocities.,EEG,recorded,stationary,sound,motion,produced,interaural,time,differences.,explored,velocity,MOR,"potential,",spectral,perturbation,(ERSP),inter-trial,phase,coherence,(ITC),calculated,time-frequency,decomposition,signals.,slow,similarly,magnitude,cN1,cP2,components,response.,delta-to-alpha,power,remained,up,"to,","including,",highest,"velocity,",suggesting,gradual,spatial,did,induce,non-coherent,activity.,"Conversely,",abrupt,displacement,induced,theta-alpha,consistency.,findings,generated,resetting,"oscillations,",degree,considered,neurophysiological,indicator,"processing.
",currently,thought,full,glycogen,molecule,(β-particle),spherical,shape,12,concentric,tiers,residues,glycogenin,center,diameter,about,42,nm.,"However,",structure,β-particle,remains,poorly,understood.,"study,",β-particles,hepatocytes,starved,situ,cytofluorometry,technique,measurement,speed,staining,Schiff's,reagent.,measurements,molecules,quickly,"stained,",labile,fraction,(LF),represents,internal,"molecule,",while,slowly,stable,(SF),external,proteins.,predicts,3rd,4th,(42%,all),bound,7th,8th,together,~19%,tier,never,proteins,enzyme,amount,particle,surface,variable.,"Thus,",makes,possible,obtain,data,particular,"cell.
",Background,"Eculizumab,",terminal,complement,reduced,relapse,placebo,anti-aquaporin-4,immunoglobulin,G-positive,(AQP4+),neuromyelitis,optica,spectrum,disorder,(NMOSD),PREVENT,trial.,report,efficacy,safety,analyses,Asian,open-label,extension,(OLE).,Methods,"double-blind,","randomized,",3,AQP4+,NMOSD,randomly,(2:1),receive,intravenous,eculizumab,(maintenance,"dose,",1200 mg/2,weeks),placebo.,completed,OLE.,Analyses,performed,prespecified,subgroup,Results,Of,143,"enrolled,",52,(36.4%),included,"(eculizumab,",n = 37;,"placebo,",n = 15);,45,Most,(86.5%),concomitant,immunosuppressive,therapy.,During,"PREVENT,",one,adjudicated,occurred,receiving,six,(hazard,"ratio,",0.05;,confidence,interval:,0.01–0.35;,p = 0.0002).,An,95.2%,relapse-free,144,treatment.,Upper,respiratory,tract,"infections,","headache,",nasopharyngitis,most,common,events,subgroup.,Conclusion,Eculizumab,reduces,"NMOSD,",benefit–risk,profile,similar,benefits,maintained,during,long-term,Clinical,trial,registration,ClinicalTrials.gov,identifiers:,NCT01892345,(PREVENT);,NCT02003144,(open-label,"extension).
",task,identify,differences,synchronization,intermittent,photic,stimulation,arterial,hypertension,manifestations,moderate,cognitive,impairment,such,manifestations.,solve,used,recurrence,based,"index,",ratio,instantaneous,"frequencies,",duration,synchrosqueezed,wavelet,transform,light,series.,greater,synchronization.,manifested,photostimulation,bioelectric,"brain,",shift,frequency,range,excitation,frequency.,assessment,"origin.
",Migraine,sensitisation,trigeminovascular,system,often,accompanied,mechanical,hyperalgesia,allodynia.,mechanisms,mechanotransduction,migraine,attack,yet,unknown.,ion,channel,Piezo1,"involved,",since,expressed,trigeminal,ganglion,"neurons,","thus,",contribute,neuronal,component,system.,took,advantage,extracellular,recordings,trigeminocervical,–,relay,centre,"pathway,",directly,assess,impact,differently,applied,Yoda1,sensory,processing,spinal,level.,slightly,facilitated,ongoing,firing,central,substance,contributed,suppression,their,intravital,"microscopy,",dilation,meningeal,innervated,afferents.,"Collectively,",here,identified,modulation,selective,mechanosensitive,"channels,",provide,new,evidence,favour,role,pathogenesis.,propose,several,underlie,"Yoda1.
",Silica,silicon,"dioxide,","which,",depending,production,"method,",exist,various,amorphous,forms,varying,"area,","size,",pore,volume,"and,","result,",physicochemical,sorption,characteristics.,presence,silanol,groups,silicas,provides,possibility,functionalisation.,"addition,",developed,Aerosil,allows,composites,content,biologically,active,substances.,"work,",biocompatibility,composite,380,carboxylated,fullerene,"C60[C(COOH)2]3,",namely:,haemolysis,(spontaneous,"photoinduced),",platelet,"aggregation,",binding,"HSA,",cyto-,"genotoxicity,",antiradical,Interest,creation,nanomaterial,fact,fullerenes,applications,fields,"biomedicine,",ability,bind,reactive,oxygen,"species,",inhibition,tumour,"development,",inactivation,viruses,bacteria.,immobilisation,drugs,"theranostics.
",TNF-α,inflammatory,cytokine.,stem,regions,carotid,"bodies,",organs,monitoring,O2.,hypothesised,circulating,necrosis,(TNF)-α,affect,ventilation,modulate,hypoxic,ventilatory,cyclooxygenase,(COX),(NOS),pathways.,compare,before,pretreatment,diclofenac,L-NG-nitro,arginine,methyl,ester,(L-NAME),nonspecific,COX,"NOS,",respectively.,anaesthetised,rebreathing,techniques.,normoxia,hypoxia.,Pretreatment,each,TNF-α.,believe,NOS-related,pathways,“cross-talk”,mediates,underlies,inflammation,"function.
","ABSTRACT
",HLA-haploidentical,transplantation,(haplo-HCT),post-transplantation-cyclophosphamide,(PT-Cy),feasible,procedure,children,malignancies.,Haplo-HCT,PT-Cy,childhood,acute,lymphoblastic,leukemia,(ALL),lacking.,haplo-HCT,180,ALL.,9,"years,",follow-up,2.7,years.,Disease,status,CR1,"24%,",CR2,"45%,",CR+3,"12%,",19%.,day,+3,+4.,Bone,marrow,(BM),source,115,(64%).,Cumulative,incidence,42-day,engraftment,88.9%.,day-100,graft-versus-host,(GVHD),grade,II-IV,"28%,",2-year,chronic,GVHD,21.9%.,cumulative,nonrelapse,(NRM),19.6%.,41.9%,25%,CR1.,Estimated,"65%,","44%,",18.8%,transplanted,"CR1,","CR2,",CR3+,3%,year,disease.,multivariable,(CR2,[hazard,{HR} = 2.19;,"P = .04]),",HCT,older,13,(HR = 2.07;,P = .03),peripheral,(PBSC),(HR = 1.98;,P = .04),survival.,PBSC,NRM,(HR = 3.13;,P = .04).,option,"ALL,",namely,those,CR2.,Age,remain,important,outcomes.,BM,improved,"survival.
","Summary
",COVID-19,pandemic,having,profound,mental,health,consequences,many,people.,Concerns,"that,","extreme,",manifest,suicide,aimed,early,rates,around,"world.
",sourced,countries,areas,through,systematic,internet,search,recourse,networks,published,literature.,Between,Sept,Nov,"1,","2020,",searched,official,websites,countries’,ministries,"health,",police,"agencies,",government-run,statistics,agencies,"equivalents,",translated,terms,“suicide”,“cause,"death”,",broadening,attempt,other,public,sources.,Data,given,country,they,came,government,available,monthly,least,Jan,"2019,",July,"31,",2020.,Our,searches,restricted,more,million,residents,pragmatic,"reasons,",relaxed,rule,literature,networks.,Areas,populations,million.,interrupted,time-series,trend,suicides,(from,March,2020),"country,",comparing,expected,number,derived,observed,April,primary,"analysis).
","Findings
",21,(16,high-income,five,upper-middle-income,"countries),",whole-country,ten,11,countries).,Rate,ratios,(RRs),CIs,versus,numbers,began,any,area.,areas:,New,South,"Wales,",Australia,(RR,0·81,[95%,CI,0·72–0·91]);,"Alberta,",Canada,(0·80,[0·68–0·93]);,British,"Columbia,",(0·76,[0·66–0·87]);,Chile,(0·85,[0·78–0·94]);,"Leipzig,",Germany,(0·49,[0·32–0·74]);,Japan,(0·94,[0·91–0·96]);,Zealand,(0·79,[0·68–0·91]);,Korea,[0·92–0·97]);,"California,",USA,(0·90,[0·85–0·95]);,Illinois,(Cook,"County),",[0·67–0·93]);,Texas,(four,"counties),",(0·82,[0·68–0·98]);,Ecuador,(0·74,"[0·67–0·82]).
","Interpretation
",first,examine,context,multiple,countries.,"countries,",largely,unchanged,declined,pre-pandemic,period.,need,vigilant,poised,respond,situation,longer-term,economic,"unfold.
","Funding
","None.
",HIV-positive,people,inject,(PWID),experience,stigma,related,"HIV,",care,utilization,health.,help,affected,cope,intersectional,reduce,"care,",adapted,behavioral,coping,intervention,HIV,"population.
",conduct,randomized,controlled,(RCT),testing,‘Stigma,Coping,Reduce,risks,Improve,Prevention,Treatment’,(SCRIPT),"intervention,","community-based,",form,Acceptance,Commitment,Therapy,"(ACT),",PWID,living,St.,"Petersburg,","Russia.
",recruited,civil,society,organizations,(CSO),delivering,harm,services,participants,2:1,either,(three,ACT,sessions,group,format,over,month,usual,CSO,care),aims,psychological,flexibility,handle,stigma-related,"expectations,",emotions,experiences.,satisfaction,"scores.
",Stigma,targeting,outside,formal,settings,confront,negativities,lives,originating,stigma's,"barrier.
",Mutations,gene,(GBA),encoding,(GCase),cause,Gaucher,(GD),commonly,Parkinson,(PD).,Ambroxol,effective,pharmacological,chaperones,GCase.,Fourteen,GD,"(GBA-PD),",thirty,enrolled.,GCase,hexosylsphingosine,(HexSph),concentration,dried,macrophage,spots,liquid,chromatography,coupled,tandem,spectrometry.,ambroxol,lysosomes,assessed,confocal,microscopy.,cultured,macrophages,patient,monocytic,(PBMC),(by,3.3-fold),3.5-fold),untreated,(p < 0.0001,"p < 0.0001,",four,days,cultivation.,HexSph,2.1-fold),1.6-fold),respectively).,colocalization,marker,LAMP2.,modes,mutant,carrying,N370S,amino,acid,substitution,pH,4.7,examined,docking,dynamics,simulations.,position,minimal,energy,close,vicinity,"residue,",370.,Taken,PBMC-derived,assessing,therapy,Rationale,&,Hemodialysis,(HD),kidney,replacement,"use,","availability,","accessibility,","affordability,",quality,HD,"worldwide.
",Study,"Design
","survey.
",Setting,"Participants
",Stakeholders,"(clinicians,",policy,"makers,",consumer,representatives),182,convened,International,Society,Nephrology,"September 2018.
","Outcomes
","Use,","care.
",Analytical,"Approach
",Descriptive,"statistics.
","Overall,",representatives,160,(88%),participated.,country-specific,maintenance,298.4,"(IQR,",80.5-599.4),per,population,(pmp).,Global,among,incident,failure,98.0,81.5-140.8),pmp,centers,4.5,1.2–9.9),pmp.,Adequate,(3-4,hours,times,weekly),generally,27%,low-income,Home,36%,32%,patient-reported,outcomes;,"61%, monitoring",small-solute,clearance;,"60%, monitoring",bone,mineral,markers;,"51%, monitoring",survival;,"60%,",initiation,"dialysis,",5%,arteriovenous,access,almost,all,education,"suboptimal,",funding,procedures,"uniform,",copayments,income.,23%,pay,>75%,costs,4%,"countries.
","Limitations
",survey,"bias,",social,desirability,limited,collection,preventing,in-depth,"analysis.
","summary,",reveal,substantial,variations,global,"quality,",affordability,"worldwide,",lowest,evident,low-,lower-middle–income,prognosis,refractory,induction,chemotherapy,immunotherapy,dismal.,Salvage,allogeneic,hematopoietic,(HSCT),widely,10%,15%,cured,procedure.,Preclinical,indicate,post-transplantation,cyclophosphamide,bendamustine,(PTB),prophylaxis,regimen,graft-versus-leukemia,(GVL),establish,optimal,PTB,antileukemic,HSCT,prophylaxis.,prospective,"(NCT02799147),",administered,doses,"140,","100,",70,mg/m2,Myeloablative,conditioning,fludarabine,busulfan,single-agent,"PTB,",subsequent,combination,tacrolimus,mycophenolate,mofetil,(MMF).,Inclusion,criteria,myelogenous,(AML),course,target,≥5%,clonal,blasts,marrow.,cohort,22,AML,5,Seven,enrolled,140,(due,stopping,"rule),",Primary,documented,41%,secondary,59%.,blast,count,start,18%,"(range,",6%,97%).,Transplantation,matched,sibling,mismatched,unrelated,"15,",haploidentical,7.,Engraftment,93%,89%,complete,remission,63%,measurable,residual,After,"prophylaxis,",unusual,"complication,",cytokine,release,syndrome,"(CRS),",70%,CRS,44%.,frequent,symptoms,fever,abnormal,liver,function,tests,"67%,",pancreatitis,"63%,",skin,vasculitis,"56%,",enterocolitis,"48%,",mucosa,"37%,",disseminated,intravascular,coagulation,nervous,toxicity,26%.,HLA-mismatched,(75%,20%;,P = .0043).,Classic,44%,Grade,(67%,25%;,P = .031).,Moderate,severe,100-day,survivors,immunosuppression,(100%,18%;,P = .002).,relatively,rate,Three-year,28%,(95%,interval,"[CI],",13%,"46%),",event-free,29%,46%).,Nonrelapse,46%,"64%),",26%,11%,44%).,relapses,+100.,statistically,(P = .3481);,mg/kg,group.,Survival,ALL,(35%,0%;,P = .0157).,promising,augment,GVL,AML;,CRS-associated,necessitates,complication.,routine,application,cannot,recommended.,Combination,MMF,ameliorates,"complications,",setting,HLA-matched,allografts.,Biological,require,"elucidation.
",Previous,diagnosed,schizophrenia,(SCZ),deficits,visual,"processing,",contrast,processing.,brain-derived,neurotropic,(BDNF),measure,investigate,neuroplasticity,some,functions,like,perception.,investigated,relationship,BDNF,first-episode,SCZ,Thirty-nine,healthy,43,Contrast,sensitivity,"low,",mid-,frequencies.,First-episode,except,middle,Negative,correlations,"BDNF,","variables,",mostly,frequencies,females.,support,(i),alterations,magno-,parvocellular,pathway,functioning,(ii),highlights,importance,biomarkers,along,measures,"disorders.
","Purpose
",analyze,5-year,biochemical,disease-free,(bDFS),late,prostate,treated,pencil,beam,scanning,(PBS),proton,radiation,"therapy.
","Materials
",January,2013,"2016,",284,intensity,modulated,"(IMPT),",ultrahypofractionated,schedule,(36.25,GyE,fractions).,Five,immediately,lost,thus,excluded,analysis.,279,prospectively,collected,56.5,3.4-87.5),mean,64.5,(40.1-85.7),prostate-specific,antigen,(PSA),value,6.35,μg/L,(0.67-17.3,μg/L).,121,(43.4%),"low-risk,",125,(44.8%),"favorable,",33,(11.8%),unfavorable,intermediate-risk,cancer.,49,(17.6%),underwent,neoadjuvant,hormonal,"therapy,",adjuvant,bDFS,profiles,"evaluated.
",7-18,days).,"96.9%,","91.7%,",83.5%,"low-,","group,",Late,(Common,Terminology,Criteria,Adverse,Events,v.4),follows:,gastrointestinal:,62,"(22%),","2,","(7.2%),","3,",(0.36%);,genitourinary:,"(28.7%),",14,"(5%),",0,PSA,"(6.1%),",lymph,node,detected,Four,(1.4%),local,recurrences,detected.,Nine,(3.2%),died,deaths,"reported.
",Ultrahypofractionated,comparable,fractionation,schedules,serious,GI,GU,"toxicity.
",Cajal-Retzius,transient,elements,developing,cerebral,cortex.,express,characteristic,molecules.,One,"them,",heavy-chain,"neurofilaments,",participating,construction,mature,"networks,",believed,feature,human’s,cells.,stain,SMI-32,antibody,non-phosphorylated,horizontally,oriented,soma,bipolar,processes,labeled,layer,cortex,cats,aged,0–2,postnatal,days.,DiI,"technique,",well-developed,parallel,vertical,branches,coming,horizontal,visualized,areas.,location,general,morphology,allowing,suppose,carnivores,share,primates,developmental,"corticogenesis.
",recent,"decades,",semiconductor,lasers,successfully,rhinology.,usage,nasal,swell,(NSB),barely,studied.,research,experimental,selection,laser,exposure,mode,NSB,970 nm,diode,safe,reduction.,thermometric,wavelength,continuous,contact,2 W,10 W,step.,"cattle,",optical,region.,experiments,temperature,"data,",4 W.,demonstrate,causing,thermal,damage,adjacent,tissue.,"experiment,",improve,breathing,hypertrophy,39,vasomotor,rhinitis,NSB.,divided,Group,consisted,laser-turbinectomy,laser.,19,pathology,"laser-turbinectomy,",dynamic,observation,respiration,according,anterior,rhinomanometry,when,subgroups,t-criterion,samples,(p > 0.05).,As,result,NOSE,scale,Student's,"t-test,",(p < 0.001).,perform,subjectively,noted,insufficiency,breathing.,indicates,regulation,"airflow.
",Trace,amine-associated,(TAARs),class,G,protein-coupled,detect,biogenic,"amines,",products,decarboxylation,acids.,majority,TAARs,(TAAR2-TAAR9),described,olfactory,epithelium,sensing,innate,odors.,members,"family,","TAAR5,",limbic,projection,emotions.,mouse,line,lacking,TAAR5,(TAAR5,"knockout,",TAAR5-KO,mice),beta-galactosidase,mapping,expression.,mice,dopamine,striatal,"metabolites,",GDNF,"mRNA,",elevated,indicating,proliferation.,"Furthermore,",major,neurogenic,subventricular,"(SVZ),",subgranular,(SGZ),potentially,surrounding,ventricle.,Direct,neurogenesis,markers,doublecortin,(DCX),proliferating,nuclear,(PCNA),2-fold,SVZ,SGZ,"mice,",observations,emotional,adult,transmission.,future,antagonists,exert,antidepressant,and/or,anxiolytic,opportunity,neurodegenerative,disorders,Parkinson's,hemispheric,asymmetry,ERPs,low-frequency,oscillatory,hemispheres,stimuli,delayed,motion.,Event-related,computed,read,books,choice,(passive,listening),indicated,trajectories,perceived,graphic,tablet,(active,listening).,goal,find,lateralization,consistent,right-hemispheric,"dominance,",contralateral,neglect,interhemispheric,asymmetry.,Apparent,dominance,hemisphere,ERSP,Stronger,contralaterality,left,corresponding,“neglect,model”,delta-alpha,oscillations.,Velocity,attention,consistently,how,pattern,interrelated,motion-related,single-trial,"measures.
",Antibodies,aquaporin-4,(AQP4),water,reported,trigger,"cascade,",implicated,astrocyte,injury.,demonstrated,inhibitor,anti-AQP4,NMOSD.,reducing,across,clinically,relevant,"PREVENT.
","time-to-event,","trial,",adults,1200 mg/2 weeks),"(2:1),",stable-dose,(IST),permitted,(except,rituximab,mitoxantrone).,Post,hoc,post,IST,demographic,"characteristics,",autoimmune,"comorbidity.
",previous,"age,","sex,","region,","race,",historical,annualized,"rate,",baseline,Expanded,Disability,Status,Scale,"score,",another,disorder.,infection,regardless,"year,","disorder.
",Across,wide,"risk,",apparent,"rate.
",Trial,"registration
","(ClinicalTrials.gov).
",Carboxylated,"fullerenes,","particular,",tris-malonate,C60,"(C60[C(COOH)2]3,","CF),",great,interest,studying,"plants,",primarily,"malonate,",biological,"activity,",means,improving,crop,yield,quality.,Impact,water-soluble,derivatives,physiological,plant,state,enough.,paper,devoted,C60[C(COOH)2]3,"state,",growth,netto,productivity,"salad,","tomatoes,",spring,"barley,",wheat,initial,stages,seed,germination,vegetative,period,plants,following,reasons:,absorption,assimilation,capacity,roots,aerial,parts,plants;,moisture,substances,organs;,entering,distributing,"organs,",containing,physiologically,organic,"compounds,",cyclic,catabolism;,optimising,antioxidant,shows,indicators,seedling,"condition,",solutions,CCF = 0.001–0.1,mg·dm−3,test,"plants.
",Approximately,worldwide,peritoneal,dialysis,practice,"globe.
","clinicians,","delivery,",outcome,Responses,88%,(n=160),313,(257,nephrologists,"[82%],",non-nephrologist,physicians,"[7%],",6,professionals,"[2%],",administrators/policy,makers/civil,servants,"[5%],",others,[4%]).,85%,(n=156),responded,questions,38.1,30,156,(19%),PD-related,"questions,",Africa,(20/41),(15/22).,69%,modality,for≤10%,newly,failure.,1%,"costs,",(>75%),(out-of-pocket,expenses,incurred,patients),Asia,Average,exchange,volumes,adequate,(defined,3-4,exchanges,equivalent,automated,PD),72%,"outcomes.
",Low,makers;,explanations,underpinning,lack,granular,data;,"data.
",Large,inter-,intraregional,disparities,"world,",greatest,gaps,"Asia.
",effectiveness,regimens,dydrogesterone,management,endometriosis-related,pelvic,"Observational,","months.
","Setting
",Twenty,gynecology,clinics,"Federation.
","Patient(s)
",Three,hundred,fifty,women,years,endometriosis,"dysmenorrhea.
","Intervention(s)
",Dydrogesterone,mg,"daily,",5th,25th,menstrual,cycle,(prolonged,cyclical,regimen),continuously,(continuous,regimen).,For,cutoff,"treatment.
",Outcome,"Measure(s)
",Intensity,11-point,numerical,rating,(after,"months).
","Result(s)
",marked,prolonged,(mean,±,standard,deviation,–3.3,2.2,–3.0,"2.2,","respectively),",With,"regimens,",improvements,"pain,",analgesics,"required,",severity,"dysmenorrhea,",sexual,"well-being,",health-related,quality-of-life,parameters.,A favorable,"confirmed,",drug,reactions,"study.
","Conclusion(s)
",Prolonged,pronounced,dysmenorrhea,led,life,"well-being.
",Registration,"Number
","NCT03690765.
",Los,regímenes,de,tratamiento,didrogesterona,cíclicos,y,continuos,prolongados,son,efectivos,para,reducir,el,dolor,pélvico,crónico,en,mujeres,con,endometriosis:,resultados,del,estudio,"ORCHIDEA.
","Objetivo
",Comparar,la,efectividad,dos,diferentes,manejo,relacionado,"endometriosis.
","Diseño
",Estudio,cohortes,prospectivo,observacional,durante,seis,"meses.
","Entorno
",Veinte,clínicas,ginecológicas,Federación,"Rusa.
","Paciente(s)
",Trescientas,cincuenta,entre,años,edad,o,sin,"dismenorrea.
","Intervención(es)
",Didrogesterona,ó,veces,al,"día,",bien,los,días,25,ciclo,menestrual,(régimen,cíclico,prolongado),ininterrumpido,continuo).,Para,todas,las,pacientes,se,limitó,recogida,datos,meses,"tratamiento.
",Medida(s),resultado,"principal(es)
",Intensidad,una,escala,puntuación,numérica,puntos,(tras,"meses).
","Resultado(s)
",Se,observó,marcada,reducción,tanto,régimen,prolongado,como,continuo,(cambio,nivel,basal,medio,desviación,estándar,"-3,3","2,2","-3,0","2,2,","respectivamente),",diferencia,significativa,ambos,grupos.,Con,"regímenes,",experimentaron,mejoras,significativas,intensidad,"crónico,",número,que,requirieron,"analgésicos,",severidad,"dismenorrea,",bienestar,parámetros,calidad,vida,relacionados,salud.,confirmó,un,perfil,seguridad,favorable,"didrogesterona,",informó,reacciones,adversas,severas,medicación,"estudio.
","Conclusión(es)
",demostraron,pronunciada,dismenorrea,resultaron,marcadas,todos,estudiados,"sexual.
",Novel,strategies,needed,optimise,surgical,resection,early-stage,non-small-cell,(NSCLC).,atezolizumab,best,supportive,platinum-based,IMpower010,"randomised,","multicentre,","open-label,",done,227,sites,regions.,Eligible,resected,stage,IB,(tumours,≥4,cm),IIIA,NSCLC,Union,Internationale,Contre,le,Cancer,American,Joint,Committee,staging,(7th,edition).,(1:1),permuted-block,(block,four),(1200,days;,16,cycles,year),(observation,regular,scans,recurrence),(one,cycles).,"endpoint,",investigator-assessed,"survival,",hierarchically,II–IIIA,whose,tumours,PD-L1,"(SP263),",then,"population,",finally,intention-to-treat,(ITT),(stage,IB–IIIA).,Safety,care.,"ClinicalTrials.gov,",NCT02486718,"(active,","recruiting).
",Oct,"7,","2015,","19,","2018,",1280,resection.,1269,"chemotherapy,",whom,1005,eligible,randomisation,(n=507),(n=498);,495,32·2,(IQR,27·4–38·3),(HR,0·66;,0·50–0·88;,p=0·0039),(0·79;,0·64–0·96;,p=0·020).,ITT,HR,(0·67–0·99;,p=0·040).,Atezolizumab-related,53,(11%),"(1%).
","NSCLC,","cells,",Atezolizumab,offers,"NSCLC.
",F,Hoffmann-La,Roche,"Genentech.
",,Genetics,"Russia,
",Buspirone-dependent,Abdominal,Pain,Transmission,Within,Nucleus,Tractus,Solitarius,"Rat,
",disease:,"study,
",Reaction,mechanism,(diaminocarbene)PdII,"complexes,
",region-specific,tone,mellitus:,Opposite,acetylcholine,"5-hydroxytryptamine,
",Efficacy,carcinomas,distinct,variants:,single-center,Effects,"mellitus,
",Brain,"motion,
",Cytochemical,"hepatocytes,
",anti-aquaporin-IgG-positive,disorder:,"extension,
",Estimation,"transform,
",Differential,system:,electrophysiological,microscopy,"rats,
",Biocompatibility,nanocomposite,"C60[C(COOH)2]3,
",Cyclooxygenase,mediate,Outcomes,Unmanipulated,Haploidentical,Post-Transplant,Cyclophosphamide,Pediatric,Acute,Lymphoblastic,"Leukemia,
",Suicide,trends,pandemic:,preliminary,"countries,
",Addressing,barrier,drugs:,Design,RCT,increases,restores,patient-derived,"Parkinsonism,
",Practice,Patterns:,Survey,"Study,
",Graft-versus-Host,Prophylaxis,Post-Transplantation,Bendamustine,Refractory,Leukemia:,Dose-Ranging,Visual,"schizophrenia,
",Proton,Radiation,Treatment,Intermediate-Risk,Prostate,Cancer-5-Year,"Outcomes,
",labeling,feline,"cortex,
","body,
",trace,(TAAR5),knockout,"mice,
",Lateralization,auditory,motion:,"analysis,
",Benefits,Subgroup,"trial,
",Plant,Peritoneal,Dialysis,ORCHIDEA,Adjuvant,IB–IIIA,(IMpower010):
ВСТРЕТИЛОСЬ_РАЗ_в_2021,31,1,1,1,1,1,1,32,382,8,1,42,5,3,2,70,4,1,2,13,7,294,1,359,140,22,4,5,6,263,3,1,7,3,1,3,1,61,3,2,25,92,124,1,2,7,19,12,2,70,1,88,2,1,83,1,3,1,1,3,1,3,1,1,5,13,3,4,3,1,4,1,1,1,1,12,3,3,1,2,9,11,1,3,6,5,4,1,1,2,4,2,10,1,1,1,4,1,2,2,1,6,1,11,20,1,5,27,3,1,2,7,6,4,2,12,2,1,1,1,2,1,17,9,5,1,2,1,17,1,1,1,1,2,2,45,1,8,19,3,1,1,1,4,1,5,5,1,3,7,1,4,10,19,1,9,1,12,5,2,1,2,8,1,1,1,2,2,3,6,1,4,3,5,1,6,7,1,1,6,4,4,11,2,1,1,1,1,4,6,1,6,4,7,1,2,1,1,3,1,1,3,1,2,3,1,11,1,4,1,1,12,1,1,2,1,24,1,1,1,3,22,1,1,1,5,4,12,1,1,12,1,21,3,31,6,1,35,1,2,6,1,1,1,2,5,5,17,1,5,6,5,8,8,2,3,7,1,3,1,10,5,1,2,4,2,1,2,1,2,2,2,3,1,2,1,1,1,2,7,1,3,4,1,1,1,4,19,1,1,1,6,3,1,1,1,1,3,1,1,8,1,2,9,5,7,8,1,1,1,2,1,8,1,1,1,1,2,1,1,5,2,1,1,1,4,1,1,1,1,1,1,1,1,1,3,1,1,9,1,3,1,1,1,1,4,4,1,1,4,1,1,1,1,1,1,1,2,1,13,2,4,1,2,2,1,3,1,1,1,1,1,1,3,1,1,1,1,1,7,1,1,3,1,1,7,5,1,1,1,1,1,1,3,1,1,1,1,22,5,2,2,1,1,2,5,1,2,3,2,2,3,4,6,3,1,1,1,1,1,1,1,2,1,6,1,1,1,1,1,1,1,1,1,2,1,10,4,2,1,1,1,4,2,4,1,4,4,7,10,2,2,1,2,5,3,1,1,1,3,1,1,4,1,1,1,8,4,4,1,14,2,1,1,3,3,2,1,1,7,3,1,1,1,2,1,1,1,1,1,3,5,1,1,2,2,1,1,9,1,3,1,12,1,1,3,1,2,2,1,1,1,4,1,2,3,1,1,1,10,5,4,1,5,5,9,9,1,1,2,1,1,2,1,1,5,2,1,4,2,2,1,2,1,4,2,8,1,4,8,8,1,5,1,5,5,2,1,6,6,7,1,9,1,7,1,1,1,2,1,1,3,11,3,1,12,1,1,1,1,1,2,1,1,1,1,9,2,8,1,2,1,1,1,1,1,1,1,4,1,4,10,1,4,1,1,9,5,1,1,1,2,1,2,2,2,7,1,3,3,28,1,1,2,1,1,1,4,1,1,8,1,1,1,1,8,1,4,2,2,1,1,3,2,1,1,1,1,1,3,4,1,1,1,1,1,2,1,1,4,5,4,4,5,2,2,5,1,3,3,1,2,2,1,4,3,1,5,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,2,16,2,1,1,2,1,1,1,1,3,2,3,1,1,5,1,1,2,1,3,1,2,3,1,1,2,1,3,3,3,1,2,1,2,3,1,1,1,1,1,3,2,2,2,11,5,1,1,2,1,1,2,3,10,13,1,1,1,4,2,2,4,1,2,2,2,1,3,1,5,2,1,9,6,2,2,7,2,1,2,6,1,3,2,2,3,18,5,2,1,2,2,3,2,1,1,1,1,2,1,1,4,3,1,1,1,1,1,1,1,8,4,2,1,3,1,1,1,1,1,1,3,1,1,1,3,2,1,1,1,2,1,1,8,3,1,1,1,3,1,5,5,1,1,1,2,1,1,4,5,1,1,1,1,3,1,1,2,2,2,4,1,1,1,1,1,2,3,1,2,1,2,1,3,1,1,1,1,1,1,2,3,1,3,1,1,1,2,1,1,1,1,1,1,1,3,1,2,5,2,4,1,3,2,12,1,1,1,1,2,3,3,12,6,1,2,2,2,4,4,4,2,2,10,2,1,2,5,3,10,2,1,1,2,2,2,14,5,3,3,1,4,1,14,2,4,1,1,1,1,2,1,4,2,6,1,1,2,1,1,1,5,1,1,1,1,3,2,1,5,2,4,1,2,6,2,3,4,4,1,1,1,2,1,1,1,4,1,1,1,2,1,7,1,1,1,1,7,3,4,1,1,2,2,2,1,3,7,1,2,4,3,1,4,1,1,1,2,1,1,1,1,2,2,2,5,3,2,2,3,2,1,3,3,3,4,1,1,8,3,7,1,2,1,2,2,2,2,1,3,1,2,1,1,1,1,1,1,1,3,1,2,2,1,1,1,4,6,2,1,1,1,1,4,1,3,1,1,1,1,2,5,1,3,7,2,1,3,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,2,5,1,2,4,3,4,1,1,1,1,1,1,2,5,1,1,9,2,1,1,1,1,1,1,1,2,1,1,1,1,4,3,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,4,1,1,1,1,2,1,1,1,1,1,1,1,2,1,2,1,1,2,1,2,2,3,1,1,1,1,5,1,1,1,2,2,6,6,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,2,1,1,1,1,2,1,1,1,1,1,5,1,1,1,1,1,3,1,6,1,1,4,1,1,1,1,4,1,1,1,1,1,1,2,1,2,3,1,1,1,1,2,3,1,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,6,1,1,1,2,1,1,1,2,1,2,1,2,1,1,2,1,1,3,1,2,3,1,7,2,5,2,1,1,1,2,2,3,4,1,1,2,4,3,1,1,1,1,1,1,3,2,2,1,2,1,4,1,1,3,5,1,1,1,1,2,2,11,2,1,2,10,4,1,2,1,1,1,1,3,1,1,1,1,1,2,1,2,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,2,1,1,1,1,4,1,2,2,1,1,2,2,1,1,2,1,2,5,7,3,1,3,8,3,1,1,1,2,1,1,6,4,5,1,2,1,2,22,5,3,1,2,3,1,1,1,1,3,2,1,5,2,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,7,1,1,2,2,4,1,1,1,4,2,5,2,2,4,3,1,6,1,1,8,3,1,1,1,1,1,1,1,1,1,1,2,2,1,5,2,2,1,1,3,5,7,2,12,1,6,1,2,3,1,4,1,2,1,1,1,4,1,1,1,1,1,9,2,1,1,2,1,2,4,1,1,1,2,1,2,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,3,2,1,1,5,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,3,3,2,1,1,7,3,1,11,1,1,3,2,2,3,4,1,3,1,2,2,6,1,2,4,2,1,1,1,1,1,1,1,1,1,1,2,1,2,1,1,2,1,3,2,3,3,1,1,1,1,1,1,1,1,2,3,1,3,1,2,1,3,1,2,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,2,1,2,1,1,1,2,3,5,1,1,1,1,5,1,1,2,6,1,1,3,1,2,1,1,1,1,1,1,5,1,1,1,1,1,3,6,1,1,4,1,1,1,2,2,3,5,1,1,1,1,1,1,1,1,1,2,2,1,2,1,2,1,1,2,1,1,1,2,2,1,1,1,1,1,1,1,1,8,2,4,2,1,4,1,6,5,5,4,6,9,1,2,3,2,2,2,2,1,3,2,1,1,2,2,4,2,2,2,2,1,1,2,2,2,2,1,2,1,1,1,1,2,1,3,1,4,6,1,1,3,1,2,1,1,1,1,1,1,1,1,1,1,2,1,2,1,4,1,1,1,2,1,1,1,1,1,4,1,1,1,1,1,1,1,1,1,3,1,8,1,1,1,1,1,2,1,1,2,1,1,1,2,2,1,2,1,1,2,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,5,2,7,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,2,7,1,1,1,2,1,1,1,1,1,2,4,1,2,1,1,2,1,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,3,2,8,1,3,1,1,1,1,1,5,1,1,1,1,1,1,1,3,1,1,2,2,1,1,2,1,1,1,1,1,1,3,1,1,1,1,3,1,1,1,1,1,1,1,1,4,1,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,3,1,1,4,1,1,2,1,1,1,1,1,1,1,1,2,1,2,1,3,1,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,7,1,3,1,1,1,1,2,2,1,2,1,1,1,1,1,3,4,6,1,2,1,1,3,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,5,1,2,5,3,1,2,1,1,3,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,2,2,1,1,3,1,2,1,10,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,4,1,1,1,4,1,1,1,2,1,2,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,5,2,1,1,1,1,1,1,6,3,4,8,4,4,1,1,2,1,4,2,2,1,1,1,1,1,1,1,1,1,2,1,2,2,1,1,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,3,1,1,1,5,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,6,1,1,3,1,2,1,1,2,5,2,1,1,1,1,1,1,1,1,2,1,1,1,1,2,2,2,1,3,2,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,2,1,3,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,2,2,1,1,1,1,2,1,1,1,1,1,2,1,1,1,3,3,2,2,1,1,1,1,1,1,1,1,1,1,4,1,1,2,1,3,1,1,3,1,2,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,3,1,1,1,1,1,1,1,1,1,2,1,2,1,1,1,3,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,3,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,4,4,1,1,7,1,1,1,1,1,1,1,1,1,1,1,2,2,2,1,1,1,3,1,1,1,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,6,1,1,1,1,1,1,1,2,1,2,1,1,1,2,1,3,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,1,1,1,2,3,26,5,3,1,12,1,2,1,1,1,1,5,7,7,6,9,2,8,2,1,6,1,1,1,1,9,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,3,1,1,2,2,1,1,1,1,1,2,1,1,3,2,1,1,1,2,3,1,1,1,1,1,2,2,3,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,2,1,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,7,6,6,2,3,2,2,2,1,1,1,1,1,4,8,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,6,3,3,3,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,2,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1
